Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease

Timothy A. Clark, Hyun Pil Lee, Raj K. Rolston, Xiongwei Zhu, Michael W. Marlatt, Rudy J. Castellani, Akihiko Nunomura, Gemma Casadesus, Mark A. Smith, Hyoung-gon Lee, George Perry

1Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA; 2Geisinger Medical Center, Danville, Pennsylvania, USA; 3Swammerdam Institute for Life Sciences – Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands and Marie Curie Early Stage Training Program – NEURAD Graduate School, Göttingen, Germany; 4Department of Pathology, University of Maryland, Baltimore, Maryland, USA; 5Department of Neuropsychiatry, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi, Japan; 6Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio, USA; 7UTSA Neurosciences Institute and Department of Biology, College of Sciences, University of Texas at San Antonio, San Antonio, Texas, USA

ABSTRACT

Oxidative imbalance is one of the earliest manifestations of Alzheimer disease (AD) actually preceding the classic pathology of amyloid β deposits and neurofibrillary tangles. Clinical trials examining antioxidant modulation by a number of global interventions show efficacy, while simple supplementation has limited benefit suggesting complexity of multiple contributing factors. In this review, we highlight new insights regarding novel approaches to understanding and treating AD based on holistic views of oxidative balance including diet. (Int J Biomed Sci 2010; 6 (3): 225-227)

Keywords: apolipoprotein E; copper; free radical; iron; lipid peroxidation; oxygen species; reactive; vitamin E

INTRODUCTION

Alzheimer disease (AD) is the most common neurodegenerative disease among the elderly. Common pathological hallmarks which manifest in AD include senile plaques of amyloid-β (Aβ) aggregates and neurofibrillary tangles (NFTs) comprising of paired helical filaments (PHFs) of tau protein (1). Other irregularities include neuronal and dendritic loss, accumulation of neuropil threads and dystrophic neurites, and atrophy of the brain (2). While they are useful in diagnosing AD, pathological hallmarks do not provide insight towards understanding the pathogenesis of the disease (3).

In this review, we emphasize studies on the connection between oxidative stress and AD pathology, recent approaches to the prevention and treatment of AD. The free radical theory of aging suggests that oxidative imbalance is a major player in the degeneration of cells (4, 5). With age as the primary risk factor for AD, free radicals have been implicated as a possible origin for AD. Oxidative stress has been defined as a breaching of the intracellular capacity for removing free radicals, leading to modification of DNA, lipids, polysaccharides, and proteins (6-8) as well as the altered homeostatic balance resulting from increased antioxidant defenses. Markers for oxidative damage, including carbonyls, hydroxynonenal, and malonaldehyde are increased in AD
and essentially every form of antioxidant stress response has been reported increased in AD.

Free radicals are molecules which carry an unpaired electron, making them highly reactive and ready to gain an electron in any way possible. Superoxide, hydroxyl, nitric oxide, alkoxyl, and peroxyl radicals are the most common free radicals within cells. Other molecules are not free radicals but can lead to the production of free radicals through various chemical reactions, such as hydrogen peroxide (H₂O₂), and peroxynitrite (ONO₂). Free radicals and similar molecules are regularly classified collectively as reactive oxygen species (ROS) indicating their capacity to cause oxidative modifications within the cell. Because free radicals are unstable and highly reactive, they are kept at relatively low levels by detoxifying enzymes. ROS are a natural byproduct of the metabolic pathways of oxidative phosphorylation during cellular respiration. However, sometimes, the production of ROS can surpass the cell’s ability to remove them, resulting in the imbalance of oxidative homeostasis leading to oxidative stress (9).

Due to its elevated levels of peroxidizable fatty acids, high request for oxygen, and relative paucity of antioxidant systems, the brain is extremely sensitive to oxidative stress. Altered mitochondrial function, Aβ peptides, and the presence of trace metal ions such as iron and copper, have been identified as potential sources of oxidative stress (10-12). It is now understood that these three areas are not mutually exclusive. For example, Aβ may induce the production of ROS in the mitochondrial membrane causing subsequent oxidative damage in the early stages of disease progression. This has been shown in studies of AD patients as well as in transgenic mice overexpressing AβPP (11, 13-16). Suprisingly, redox-active transition metals collect in AD susceptible neurons (10) and, along with Aβ, can locally produce higher levels of ROS when around cytoplasmic H₂O₂ (17-19) leading to lipid and RNA oxidation (20). There are likely numerous mechanisms which cause oxidative stress to occur leading to dysfunctional neuronal responses in AD and the progression of the AD (21-23).

Antioxidant trials include the examination of exogenous or endogenous compounds, which act to scavenge ROS, inhibit ROS formation, or bind metal ions needed for ROS generation. Natural antioxidants can be classified into two major groups: enzymatic antioxidants (e.g., superoxide dismutase, catalase) and nonenzymatic cellular molecules mimicking antioxidants (Figure 1). Some common nonenzymatic molecules include glutathione (GSH), ascorbate (vitamin C), α-tocopherol (vitamin E), β-carotene, uric acid, sodium selenite, melatonin, and plasma protein thiol.

Enzymatic antioxidants have cytoprotective effects in AD model systems yet have been shown to be reduced during the disease process (24). GSH reduces free radicals in vivo yet the level of GSH is decreased both in cortex and hippocampus of patients with AD (25-27). Vitamin E is the most effective nonenzymatic antioxidant within the cell membrane and is able to reduce lipid peroxidation (28).

While it has not yet been understood, having a healthy diet has been shown to decrease AD risk. An intake of dietary vitamin C and vitamin E have been associated with a decreased risk of the disease. This relationship, however does not exist for supplement only intake (29). Fish consumption and diets rich in Omega-3 fatty acids have also been correlated with a lower risk of AD development (30). High calorie and saturated fat diets show a relationship to increased AD risk (31). Further studies are needed to understand whole food intake and long term dietary pattern as they relate to cognitive decline.

Aβ is highly redox active and generates ROS in the presence of copper and iron (19, 32, 33). Because of the high levels of redox active metals in the brain during AD, chelation may be a possible form of therapy (10). Deferoxamine, a transition metal chelator, was shown to slow the rate of decline of daily living skills (34).

So far, no clinical study has succeeded in fully stopping the progression of AD. With increasing understanding of AD pathogenesis, it is clear that the focus of AD
therapy will move to targeting oxidative stress. Ongoing studies are being done in the United States and Europe to better characterize between mild cognitive impairment and AD patients with the hope of improving clinical trials. The Alzheimer Disease Neuroimaging Initiative is currently underway between the NIH and private industry. This study will collect a wealth of data from MRI and PET scans, cognitive scores, and biomarkers, leading to more improved and more specific treatments. Understanding that the molecular mechanisms influential during disease progression should be the focus of treating AD, rather than the final pathological outcome (35), has put us another step closer to a world without AD.

ACKNOWLEDGMENTS

Work in the authors’ laboratories is supported by the National Institutes of Health and the Alzheimer’s Association. T. A. Clark is supported by the National Institutes of Health MARC U*STAR (T34GM007717) and MBRRISE (R25GM060655) programs.

Dr. Smith is a paid consultant and/or receives lecture fees from Advana, Anavex, Medivation/Pfizer, and Neurotez Pharmaceuticals.

Dr. Perry is a paid consultant for Neurotez and Takeda Pharmaceuticals.

REFERENCES

1. Cummings JL, Cole G. Alzheimer disease. Jama. 2002; 287 (18): 2335.
2. Alzheimer A. Uber einen eigenartigen schweren Krankheitsprozess der Hirnrinde. Zentralblatt fêr Nervenkrankheiten. 1906; 25: 1134.
3. Lee HG, et al. Amyloid beta: the alternate hypothesis. Curr. Alzheimer Res. 2006; 3 (1): 75.
4. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956; 11 (3): 298.
5. Harman D, Eddy DE, Noffsinger J. Free radical theory of aging: inhibition of amyloidosis in mice by antioxidants; possible mechanism. J. Am. Geriatr. Soc. 1976; 24 (5): 203.
6. Smith MA, et al. Radical AGEing in Alzheimer’s disease. Trends Neurosci. 1995; 18 (4): 172.
7. Perry G, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases? Free Radic. Biol. Med. 2002; 33 (11): 1475.
8. Perry G, et al. Reactive oxygen species mediate cellular damage in Alzheimer disease. J. Alzheimers Dis. 1998; 1 (1): 45.
9. Pratico D, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001; 21 (12): 4183.
10. Smith MA, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA. 1997; 94 (18): 9866.
11. Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer’s disease? Brain Res. Brain Res. Rev. 2005; 49 (3): 618.
12. Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004; 430 (7000): 631.
13. Manczak M, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006; 15 (9): 1437.
14. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol. Med. 2008; 14 (2): 45.
15. Hirai K, et al. Mitochondrial abnormalities in Alzheimer’s disease. J. Neurosci. 2001; 21 (9): 3017.
16. Castellani R, et al. Role of mitochondrial dysfunction in Alzheimer’s disease. J. Neurosci. Res. 2002; 70 (3): 357.
17. Sayre LM, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals. J. Neurochem. 2000; 74 (1): 270.
18. Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 1998; 799 (1): 91.
19. Huang X, et al. The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 1999; 38 (24): 7609.
20. Nonomura A, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer’s disease. J. Neurosci. 1999; 19 (6): 159.
21. Zhu X, et al. Alzheimer disease, the two-hit hypothesis: an update. Biochim. Biophys. Acta. 2007; 1772 (4): 494.
22. Zhu X, et al. Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol. 2004; 3 (4): 219.
23. Zhu X, et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis. Mech. Ageing Dev. 2001; 123 (1): 39.
24. Bruce AJ, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 1996; 2 (7): 788.
25. Adams JD Jr, et al. Alzheimer’s and Parkinson’s disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol. Chem. Neuropathol. 1991; 14 (3): 213.
26. Jenner P. Oxidative damage in neurodegenerative disease. Lancet. 1994; 344 (8925): 796.
27. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull. 1995; 31 (1): 159.
28. Sung S, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease. Faseb J. 2004; 18 (2): 323.
29. Morris MC, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002; 287 (24): 3230.
30. Morris MC, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003; 60 (7): 940.
31. Luchsinger JA, et al. Caloric intake and the risk of Alzheimer disease. Arch. Neurol. 2002; 59 (8): 1258.
32. Hayashi T, et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic. Biol. Med. 2007; 43 (11): 1552.
33. Nakamura M, et al. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry. 2007; 46 (44): 12737.
34. Crapper McLachlan DR, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet. 1991; 337 (8753): 1304.
35. Castellani RJ, et al. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta. Neuropathol (Berl). 2006; 111 (6): 503.